A double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders
- PMID:16190799
- DOI: 10.1089/cap.2005.15.682
A double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders
Abstract
Objective: The aim of this study was to study valproate efficacy and safety for aggression in children and adolescents with pervasive developmental disorders (PDD).
Methods: In this prospective double-blind, placebo-controlled study, 30 subjects (20 boys, 10 girls) 6-20 years of age with PDD and significant aggression were randomized and received treatment with valproate (VPA) or placebo (PBO) for 8 weeks as outpatients. Mean VPA trough blood levels were 75.5 mcg/mL at week 4 and 77.8 mcg/mL at week 8.
Results: No treatment difference was observed statistically between VPA and PBO groups. The Aberrant Behavior Checklist--Community Scale (ABC-C) Irritability subscale was the primary outcome measure (p = 0.65), and CGI--Improvement (p = 0.16) and OAS (p = 0.96) were secondary outcome measures. Increased appetite and skin rash were significant side effects. Only 1 subject was dropped from the study owing to side effects, notably a spreading skin rash, which then resolved spontaneously. Two subjects receiving VPA developed increased serum ammonia levels, one with an associated parent report of slurred speech and mild cognitive slowing. Poststudy, of 16 VPA and PBO subjects receiving VPA, 10 subjects demonstrated sustained response, 4 of whom later attempted taper, with significant relapse of aggression.
Conclusion: The present negative findings cannot be viewed as conclusive, partly owing to the large placebo response, subject heterogeneity, and size of the groups. Larger studies are needed to expand upon these findings.
Similar articles
- The overt aggression scale for rating aggression in outpatient youth with autistic disorder: preliminary findings.Hellings JA, Nickel EJ, Weckbaugh M, McCarter K, Mosier M, Schroeder SR.Hellings JA, et al.J Neuropsychiatry Clin Neurosci. 2005 Winter;17(1):29-35. doi: 10.1176/jnp.17.1.29.J Neuropsychiatry Clin Neurosci. 2005.PMID:15746480Clinical Trial.
- Yokukansan (TJ-54) for irritability associated with pervasive developmental disorder in children and adolescents: a 12-week prospective, open-label study.Wake R, Miyaoka T, Inagaki T, Furuya M, Ieda M, Liaury K, Kishi K, Horiguchi J.Wake R, et al.J Child Adolesc Psychopharmacol. 2013 Jun;23(5):329-36. doi: 10.1089/cap.2012.0108.J Child Adolesc Psychopharmacol. 2013.PMID:23782127Clinical Trial.
- Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders.Hollander E, Chaplin W, Soorya L, Wasserman S, Novotny S, Rusoff J, Feirsen N, Pepa L, Anagnostou E.Hollander E, et al.Neuropsychopharmacology. 2010 Mar;35(4):990-8. doi: 10.1038/npp.2009.202. Epub 2009 Dec 9.Neuropsychopharmacology. 2010.PMID:20010551Free PMC article.Clinical Trial.
- Pharmacotherapy of irritability in pervasive developmental disorders.Stigler KA, McDougle CJ.Stigler KA, et al.Child Adolesc Psychiatr Clin N Am. 2008 Oct;17(4):739-52, vii-viii. doi: 10.1016/j.chc.2008.06.002.Child Adolesc Psychiatr Clin N Am. 2008.PMID:18775367Review.
- Managing irritability and aggression in autism spectrum disorders in children and adolescents.Robb AS.Robb AS.Dev Disabil Res Rev. 2010;16(3):258-64. doi: 10.1002/ddrr.118.Dev Disabil Res Rev. 2010.PMID:20981764Review.
Cited by
- Clinical Assessment, Genetics, and Treatment Approaches in Autism Spectrum Disorder (ASD).Genovese A, Butler MG.Genovese A, et al.Int J Mol Sci. 2020 Jul 2;21(13):4726. doi: 10.3390/ijms21134726.Int J Mol Sci. 2020.PMID:32630718Free PMC article.Review.
- Chloride imbalance in Fragile X syndrome.Miles KD, Doll CA.Miles KD, et al.Front Neurosci. 2022 Oct 12;16:1008393. doi: 10.3389/fnins.2022.1008393. eCollection 2022.Front Neurosci. 2022.PMID:36312023Free PMC article.
- Obesity in children with autism spectrum disorder.Curtin C, Jojic M, Bandini LG.Curtin C, et al.Harv Rev Psychiatry. 2014 Mar-Apr;22(2):93-103. doi: 10.1097/HRP.0000000000000031.Harv Rev Psychiatry. 2014.PMID:24614764Free PMC article.Review.
- Anticonvulsants for Psychiatric Disorders in Children and Adolescents: A Systematic Review of Their Efficacy.Davico C, Canavese C, Vittorini R, Gandione M, Vitiello B.Davico C, et al.Front Psychiatry. 2018 Jun 22;9:270. doi: 10.3389/fpsyt.2018.00270. eCollection 2018.Front Psychiatry. 2018.PMID:29988399Free PMC article.
- Pharmacological interventions for challenging behaviour in children with intellectual disabilities: a systematic review and meta-analysis.McQuire C, Hassiotis A, Harrison B, Pilling S.McQuire C, et al.BMC Psychiatry. 2015 Nov 26;15:303. doi: 10.1186/s12888-015-0688-2.BMC Psychiatry. 2015.PMID:26611280Free PMC article.Review.
Publication types
MeSH terms
Substances
Related information
Grants and funding
LinkOut - more resources
Full Text Sources